ArticleEJHaem2026
Thrombotic Events in Patients With Paroxysmal Nocturnal Haemoglobinuria Using Eculizumab: A Post-Marketing Surveillance Sub-Analysis.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thrombotic events (TEs) account for approximately 40%-67% of deaths in untreated paroxysmal nocturnal haemoglobinuria (PNH). C5 inhibitor treatment (e.g., eculizumab and ravulizumab) greatly reduces the incidence of TEs in patients with PNH, but data on the characteristics of PNH patients experiencing TEs are limited. Methods: This post-marketing surveillance sub-analysis evaluated the incidence of TEs in patients with PNH in Japan. Results: During eculizumab treatment, 54 TEs occurred in 44/794 patients (5.5%), an incidence of 1.50/100 patient-years. The most frequent TEs were deep vein thrombosis and cerebral infarction (eight events [14.8%]). A history of TE before eculizumab treatment was associated with TE during eculizumab treatment ( Conclusion: Eculizumab helps prevent TEs in PNH. TE events appear to be associated with higher LDH levels, infections and long dosing intervals. Concurrent antithrombotic agent use to prevent TEs in PNH is likely clinically useful, especially in patients with a history of TE. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.